Following on from information provided to NICE by the company in September 2017, the appraisal of Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued.
| Status | Discontinued |
| Technology type | Medicine |
| Decision | Selected |
| Process | TA |
| ID number | 1071 |
Email enquiries
- If you have any queries please email scheduling@nice.org.uk
Timeline
Key events during the development of the guidance:
| Date | Update |
|---|---|
| 23 January 2023 | Discontinued. Following on from information provided to NICE by the company in September 2017, the appraisal of Pembrolizumab for treating relapsed metastatic colorectal cancer with high microsatellite instability [ID1071] was suspended from NICE’s work programme. As no further information has been received from the company the topic has been discontinued. |
| 20 December 2017 | Draft scope documents |
| 19 October 2017 | Following on from advice received from the company, the timelines for this appraisal remain to be confirmed. NICE has decided to suspend this appraisal on its current work programme, however, as this appraisal has been referred, we will continue to monitor any development and will update interested parties if and when the situation changes . |
| 12 September 2017 | Suspended. This appraisal has been suspended following discussions with the company. |
| 22 July 2016 | Referral |
For further information on our processes and methods, please see our CHTE processes and methods manual